Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen reports positive psoriatic arthritis data for Simponi Aria

Janssen reports positive psoriatic arthritis data for Simponi Aria

15th June 2017

Janssen has announced new clinical trial data that demonstrates the safety and efficacy of Simponi Aria in the treatment of psoriatic arthritis.

Data from the pivotal phase III GO-VIBRANT study showed that the intravenously administered anti-TNF-alpha therapy delivered significant inhibition in the progression of structural damage.

It was demonstrated that 75.1 percent of patients with active psoriatic arthritis receiving Simponi Aria achieved at least a 20 percent improvement in arthritis signs and symptoms at week 14, compared with 21.8 percent of patients receiving placebo.

The drug was also linked with significant improvement across all secondary endpoints evaluating improvements in skin symptoms, joint damage and health-related quality of life measures.

Simponi Aria is currently under review by regulators for the treatment of adults with active psoriatic arthritis and ankylosing spondylitis, having already been approved as a treatment for rheumatoid arthritis in combination with methotrexate.

Dr Newman Yeilding, head of immunology development for Janssen's research and development unit, said: "Data from the GO-VIBRANT study demonstrated how Simponi Aria, a product already helping people living with moderately to severely active rheumatoid arthritis, may also help those living with psoriatic arthritis."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801836872-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.